Managers

Akouos fetches $7.5 mln seed

Akouos, a new biotechnology company focused on restoring and preserving hearing, has raised $7.5 million in seed funding. The lead investors were 5AM Ventures and New Enterprise Associates. Partners Innovation Fund also participated in the round. In conjunction with the funding, Kush Parmar, a managing partner at 5AM Ventures and Ed Mathers, a partner at New Enterprise Associates, have joined the Akouos board of directors.

Fractyl nets $44 mln Series D

Lexington, Massachusetts-based Fractyl Laboratories Inc, a medical tech company, has raised $44 million in Series D financing. The investors included GV, True Ventures, the IDO Fund, General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners, L.P. and Deerfield Management Company L.P.

Flare Capital backs VisitPay

Boise, Idaho-based VisitPay, a platform for patient financial health, has secured an undisclosed amount of funding. The investor was Flare Capital Partners.

Semma Therapeutics racks up $114 mln Series B

Cambridge, Massachusetts-based Semma Therapeutics, a biotechnology company focused on developing new regenerative medicines, has secured $114 million in Series B financing. Eight Roads Ventures and Cowen Healthcare Investments led the round with participation from other investors that included MPM Capital, F-Prime Capital Partners, ARCH Venture Partners, Novartis, Medtronic, JDRF T1D Fund, ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital and SinoPharm Capital. In conjunction with this financing, Semma has added Daniel Auerbach from Eight Roads and Kevin Raidy from Cowen to its board of directors.

ResTORbio locks in $40 mln Series B

Boston-based ResTORbio Inc, a clinical-stage biopharmaceutical company focused on treating aging-related diseases, has closed $40 million in Series B financing. OrbiMed led the round with participation from other investors that included Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio.

TetraVue lands funding

Vista, California-based TetraVue, a provider of advanced 3D technology, has secured an undisclosed amount of funding. TetraVue's backers include KLA Tencor, Lam Research, Tsing Capital, Robert Bosch Venture Capital GmbH, Samsung Catalyst Fund and Nautilus Ventures.

VC Video Interview with Mamoon Hamid: Future programmers could be blue-collar workers

Temasek, Tencent among backers of Real Ventures IV’s C$180 mln close

Temasek, Tencent among backers of Real Ventures IV’s $180 mln close

Real Ventures has raised $180 million for its fourth early-stage fund with the help of an expanded LP base, including two powerhouse Asian investors won over by the firm’s artificial-intelligence strategy. The Montréal venture firm this week announced the close of Real Ventures IV at its hard cap. It is backed by more than 60 LPs, among them new LPs Caisse de dépôt et placement du Québec, Boston-based HarbourVest, Singapore sovereign-wealth fund Temasek and Chinese tech giant Tencent. They join returning LPs Teralys Capital, BDC Capital and Investissement Québec.

New Mexico approves up to $125 mln for KKR, EnCap Flatrock